Advances in oral therapy for multiple myeloma

Area of Science:

• Oncology
• Pharmacology

Background:

• Conventional chemotherapy for multiple myeloma is toxic and impacts patient quality of life.
• Multiple myeloma remains incurable with standard treatments, necessitating novel therapeutic approaches.

Purpose of the Study:

• To review emerging oral therapies for multiple myeloma.
• To highlight treatments targeting myeloma cells and bone marrow with improved safety profiles.

Main Methods:

• Review of early-stage development drugs with antimyeloma activity.
• Discussion of targeted therapies including FGFR3, IGF-1R, and VEGF inhibitors.
• Exploration of epigenetic modifiers like histone deacetylase inhibitors.

Main Results:

• Several novel oral agents demonstrate significant antimyeloma activity.
• Immunomodulatory drugs (thalidomide, lenalidomide) are effective with low toxicity.
• Targeted inhibitors (CHIR-258, NVP-ADW742, PTK787) show promise.

Conclusions:

• New oral treatments have the potential to transform multiple myeloma management.
• Sequential or combination use of these agents may render multiple myeloma a chronic disease.
• Improved patient outcomes, extended lifespan, and enhanced quality of life are anticipated.